Search Results for "Sjogren A Belimumab"

11:57 EST 14th February 2016 | BioPortfolio

Matching Channels


Matching News


Class: Immunotherapy Generic Name: Belimumab Trade Name: Benlysta® For which conditions is this drug approved? Benlysta is approved to treat adults with active systemic lupus erythematosus (SLE or lu...

Regulatory update – BLA filed for Benlysta® (belimumab)

GlaxoSmithKline PLC (GSK) announced today that Human Genome Sciences, Inc. (HGS) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), for Benlysta (belim...

Regulatory update - Benlysta® (belimumab)

GlaxoSmithKline PLC (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), for Benlysta (belimumab) for reducing disease activi...

GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis

GSK today announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis - a condition that involves inf...

Stratifying primary Sjögren’s syndrome: killers in the balance?

The article by Seror et al. in Arthritis Research & Therapy reports data from the 15 French patients in the open-label BELISS (Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Synd...

GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus

GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta (belimumab) as a potent...

Families with SLE Face Risk for Sjogren’s Syndrome (CME/CE)

(MedPage Today) -- Two autoimmune diseases share clinical and serological features

GSK Announces Positive Results From Phase III BLISS-SC Study of Benlysta® (Belimumab) Administered Subcutaneously In Patients With Systemic Lupus Erythematosus (SLE)

SAN FRANCISCO and LONDON, Nov. 10, 2015 /PRNewswire/ -- On Saturday, Nov. 7, GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lup...

Matching PubMed Articles

A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.

Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab and standard SLE therapies in patients af...

Belimumab in systemic lupus erythematosus: a perspective review.

Belimumab (Benlysta(®)) is a fully humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was approved by...

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

The purpose of this analysis is to evaluate the cost-effectiveness of belimumab, a new biological treatment specifically developed for the treatment of Systemic Lupus Erythematosus (SLE), in the Itali...

Rare association: Sjogren Syndrome and liposarcoma of the parotid.

Association Gougerot Sjogren syndrome and celiac disease.

Search Whole site using Google

Quick Search
Advertisement Advertisement